Abstract
The progesterone receptor (PR) is a critical regulator of hormone signaling in breast tissue, with its 2 primary isoforms, PR-A and PR-B, exhibiting distinct and sometimes opposing functions. These isoforms arise from alternative promoter usage within the PGR gene, resulting in structural differences that influence their transcriptional activity, regulatory interactions, and post-translational modifications. This review explores the historical discovery of PR isoforms, their structural and functional differences, and the molecular mechanisms governing their transcriptional regulation. We also discuss their physiological roles in normal mammary gland development and how their dysregulation contributes to breast cancer progression, endocrine resistance, and cancer stem cell expansion. Understanding the distinct roles of PR isoforms in breast cancer biology holds significant implications for developing targeted therapeutic strategies aimed at modulating isoform-specific PR activity in hormone-driven cancers.
Keywords
progesterone receptors, breast cancer, transcriptional regulation, steroid receptors, steroid hormones
The progesterone receptor (PR), a member of the nuclear receptor superfamily, plays a critical role in mediating the effects of progesterone in normal physiology and disease. Early studies identified 2 main PR isoforms, PR-A and PR-B, which arise from alternative transcription start sites within the PGR gene. While PR-B is the full-length receptor with robust transcriptional activity, PR-A lacks the N-terminal “B-upstream segment” or BUS domain, resulting in distinct functional properties. These seminal discoveries laid the foundation for understanding how PR isoform balance influences both normal mammary gland development and breast cancer progression.
Discovery and Characterization of PR Isoforms
The existence of 2 progesterone receptor (PR) isoforms, PR-A and PR-B, was first observed in the 1970s through studies of the chick oviduct, where researchers identified 2 distinct progesterone-binding proteins in roughly equimolar ratios (1, 2). These proteins encoded a full-length receptor, PR-B, and a truncated version, PR-A, which lacks the first 164 amino acids present in PR-B. This foundational discovery laid the groundwork for understanding their structural and functional differences. Subsequent work by Conneely et al (3) provided definitive evidence that PR-A and PR-B are expressed from a single gene through alternative promoter selection (Fig. 1) and demonstrated that these isoforms are conserved across both rodent and human tissues.
Building on this knowledge, Kastner et al (4) elucidated the modular structure of the PR, including the transactivating domains (later termed AF1 and AF2; Fig. 2) that govern transcriptional activity, and predicted that selective mutations could be used to ablate individual isoform expression. Dobson et al (5) further highlighted the importance of the PR-B-specific amino-terminal region, identifying the unique transactivation domain (AF3) that contributes to PR-B's stronger transcriptional activity compared to PR-A. In 1990, Shyamala et al (6) demonstrated that the expression ratio of PR isoforms is developmentally and hormonally regulated, varying across reproductive tissues under different physiological conditions. Graham et al (7) were the first to evaluate PR isoform expression in breast cancer patient samples, however Hopp et al (8) were the first to correlate altered PR-A to PR-B ratios with breast cancer progression and response to tamoxifen. Finally, functional studies using knockout mouse models by Conneely et al (9) revealed distinct physiological roles for each isoform: PR-A is essential for ovarian and uterine function, while PR-B is required for normal mammary gland development. Collectively, these foundational studies established the structural, functional, and physiological distinctions between PR-A and PR-B, setting the stage for decades of research into their roles in tissue homeostasis and disease.
Structural Features and Post-Translational Modifications
PR isoforms function as both ligand-activated transcription factors and mediators of rapid cytoplasmic signaling. They regulate the cellular response to progesterone and act as hubs for transmitting intracellular signaling cues, collectively contributing to a broad range of cellular processes. Their diverse functions are influenced by structural domains (Fig. 2), post-translational modifications (PTMs), and direct and indirect interactions with rapid signaling pathways.
PR Isoforms and Their Dimerization Dynamics
All PR isoforms arise from a single gene, PGR, located on chromosome 11q22-23. PR-A and PR-B are transcribed through alternative promoter usage, leading to distinct mRNA transcripts (Table 1) and functional proteins with key functional domains (Fig. 2) (10, 11). As stated above, PR-B contains an additional B-upstream segment (BUS) spanning the first 164 amino acids (aa) in the N-terminal domain (NTD) which is absent on PR-A (12). Despite the early identification of the dual promoter in the PGR gene, limited data exists to date on the regulation of PR-A and PR-B expression ratios at the genomic level.
Table 1.
| Isoform | Ensembl Transcript ID | Protein features | Function/localization |
|---|---|---|---|
| PR-B | ENST00000325455.10 | Full-length (933 aa) isoform with an additional N-terminal segment (164/165 aa, called BUS) conferring a unique activation function (AF3). | Nuclear receptor; genomic actions of progesterone. |
| PR-A | ENST00000619228.2 | Shorter isoform lacking the N-terminal 164/165 amino acids present in PR-B. | Nuclear receptor; genomic actions of progesterone. |
| PR-C | Not clearly annotated in Ensembl. | Truncated isoform (∼45-50 kDa), results from translation at Met-595; lacks AF1, AF3, and most of the DBD. | Poorly characterized; cannot bind DNA but may modulate other PR isoforms. |
| PR-M | Not clearly annotated in Ensembl. | N-terminal mitochondrial targeting sequence. | Mitochondria; mediates rapid, nongenomic signaling. |
| PR-S | Not clearly annotated in Ensembl. | Splice variant with a novel exon (“exon S”) before exon 4 and exons 4 to 8 of the PR gene; lacks the DBD but retains the LBD. | Tissue-specific; may regulate nongenomic signaling. |
| PR-T | Not clearly annotated in Ensembl. | Splice variant with a novel exon (“exon T”) before exon 4 and exons 4 to 8 of the PR gene; lacks the DBD but retains the LBD. | Tissue-specific; may regulate nongenomic signaling. |
Other PR splice variants (Table 1) have been identified that play various roles in both male and female reproduction. PR-C was first described as a truncated isoform derived from AUG595 (13), incapable of binding DNA alone. PR-M is a mitochondrial-localized receptor derived from an alternative transcript. Its association with the mitochondria suggests a role for mediating rapid, nongenomic responses to progesterone in cellular energy metabolism, distinct from transcriptional regulation (14). PR-S and PR-T are lesser-known progesterone receptor isoforms identified from the human testis cDNA library (15). Both isoforms contain unique upstream exons (exon S for PR-S and exon T for PR-T) followed by exons 4 to 8 of the PR gene, resulting in proteins that lack the DNA-binding domain but retain the ligand binding domain (LBD), that is, the progesterone-binding domain, enabling them to mediate nongenomic signaling and recruit cofactors. Some controversy remains about the roles of the less well characterized PR variants (PR-C, PR-M, PR-S, PR-T) due to difficulty detecting their endogenous expression in in vitro models (16). These variants likely have low basal expression levels and have highly tissue-specific functions that have yet to be fully delineated.
The main differential functions of the 2 transcriptionally active isoforms, PR-A and PR-B, can be attributed to interactions between transactivating domains or activation function (AF) domains, AF-3, AF-1, and AF-2, that promote ligand-independent transcriptional activation and coregulator recruitment (17). PR-B uniquely possesses AF-3 (aa 54-154; Fig. 2) in the BUS, contributing to its stronger ligand-dependent transcriptional activity when compared to PR-A (12). AF-3 contains 2 phosphorylation sites: a ligand-dependent site at aa81 that is phosphorylated by casein kinase II (CK2), and a ligand-dependent site at aa102 with a Ser-Pro motif which implicates the proline-directed kinases, cyclin dependent kinases (CDKs) and mitogen-activated protein kinase (MAPKs) (18) in its phosphorylation. The intrinsically disordered NTD region on both isoforms contains multiple PTM sites that regulate PR stability, nuclear translocation, DNA binding, and chromatin interactions further described in following sections.
Ligand-dependent transcriptional activity relies on the LBD AF-2 to mediate receptor interactions and dimerization. Agonist binding to the LBD causes conformational shift in a key alpha-helix in the AF2 domain affecting dimerization interface (19, 20). In addition to the LBD interface, the hinge region and DNA-binding domain (DBD) are required for efficient receptor-receptor dimerization interactions (20).
The DBD enables PR to dimerize and bind to receptor-specific hormone response elements, that is, progesterone response elements (PREs), in target gene promoters and distal enhancers (21, 22). The DBD formation consists of 2 zinc DNA-binding modules and 2 alpha-helices, which contributes to its globular structure and is conserved across other nuclear hormone receptors. These zinc-finger motifs ensure sequence specificity and facilitate coregulator recruitment (23, 24). The progesterone response element sequence homology is highly conserved between the steroid response elements (SRE) for the androgen, glucocorticoid, and mineralocorticoid receptors (25-29). Thus, the DBD groove amino acids of PR interact with DNA bases and acetylation in a strikingly similar fashion to those reported for the glucocorticoid receptor and androgen receptor (30, 31). The palindromic nature of the canonical hormone response element implicates dimer binding preference and yields the highest binding affinity for SR dimers (32-34). Although dimerization can occur in the absence of DNA (35), the DBD, hinge, and LBD are required.
Although PR-A exhibits an overall stronger dimerization potential than PR-B, B/B homodimers can outcompete A/A homodimers with regard to transcriptional activation (Fig. 3). The more potent transcriptional activity of PR-B relative to PR-A isoforms likely occurs via PR-B's AF-3-mediated functions and higher affinity for coactivators (36, 37). This may contribute to PR-A's observed dominant-negative effects on PR-B. For example, A/B heterodimers in which A is rendered inactive via DBD mutation or binding of antagonist can repress PR-B transcriptional output (38). The combination of strong PR-A dimerization potential and lack of the AF3 domain appear to provide PR-A with the ability to sequester PR-B, thereby inhibiting B/B homodimerization, strong transactivation, and cofactor binding (22). These complex interactions likely function to tightly regulate downstream transcriptional profiles and changes in the normal 1:1 ratio of the isoforms ultimately impact gene expression and phenotypic outcomes of PR activation (discussed in later sections). For example, we predict that in healthy cells, the balance between PR isoforms leads to strong B/B transactivation that is kept in check by PR-A.
PR-C may also act as a negative regulator of PR-B. Although overexpression of PR-C in the laboring myometrium correlates with elevated PR-B levels, a PR-C-dominant ratio triggers functional progesterone withdrawal by sequestering ligand from PR-B, thus blocking DNA binding (39). This shift is driven by NF-κB pathway activation in humans and mice, and inhibits PR transactivation, disrupting uterine quiescence to promote labor. Additionally, due to the N-terminally truncated DBD of PR-C (Fig. 2), homodimerization is not possible. B/C heterodimers are capable of forming but fail to bind DNA as tightly as those with a full-length DBD on both dimer partners (40) (Fig. 3). The lack of AF-3 on PR-C promotes PR-A-like behavior, reducing cofactor binding and limiting PR-B transcriptional potential.
Rapid Signaling and Crosstalk With Kinase Pathways
Beyond its genomic functions, PR engages in rapid, nongenomic signaling through direct interactions with the mediators of cytoplasmic and cell membrane-associated kinase cascades (eg, c-src, EGFR, PI3K). These interactions can occur in a ligand-dependent manner or via modulation of ligand-independent PR activity in response to signal-generated PTMs. For example, PR interacts with Src-family kinases through its NTD, leading to activation of the MAPK and PI3K/Akt pathways (Fig. 2), which promote phosphorylation of PR and changes in cell proliferation and survival. Src-homology 3 (SH3) domains in p60-src kinases and other receptors bind directly to proline-rich motifs on PR, facilitating these interactions (41). PR isoforms exhibit differential activation of mitogenic protein kinase pathways; PR-B uniquely activates c-src and p44/p42 MAPK in vivo, whereas both PR-A and PR-B activate the c-src-related kinase HcK in a ligand-dependent manner (41, 42).
PR signaling crosstalk with kinase pathways can be initiated by growth factors such as EGF and IGF-1, amplifying mitogenic responses. PR activity peaks during the S phase of the cell cycle and declines in G0/G1 (43). Additionally, progestin-mediated MAPK activation upregulates cyclins D1 and E which associate with PR, further supporting PR's role in cell cycle progression (44).
Post-Translational Modifications of PR
PR undergoes multiple PTMs that regulate its localization, transcriptional function, and stability. PR contains at least 14 phosphorylation sites (45). Hormone-independent phosphorylation occurs at Ser81, Ser162, Ser190, and Ser400 (18), while Ser102, Ser294, and Ser345 are progestin-dependent (46). MAPK or CDK2 phosphorylate Ser294 in response to either progesterone or independently of ligand via growth factor–initiated signaling events. Phosphorylation of PR Ser294 promotes ligand-dependent PR hyperactivation at a subset of p-Ser294-PR target genes, followed by ubiquitination and degradation (47-49). Found in the BUS (ie, unique to PR-B), Ser81 is phosphorylated by CK2 and confers PR-B transcriptional specificity. Although basal or ligand-independent Ser81 phosphorylation clearly occurs, this event is also progesterone-induced (ie, increases further upon progesterone treatment) (50). Interestingly, a phospho-mutant PR-B receptor containing a point mutation at Ser81 (S81A) phenocopies the PR-A isoform with regard to target gene regulation, presumably because Ser81 regulates key BUS functions such as coactivator recruitment (50).
SUMOylation sites within the NTD (Fig. 2), particularly SUMO-1 consensus sites, suppress cooperative interactions between AF-1, AF-3, and AF-2 in the LBD (51), providing a balance to both isoforms as well as PR-B with the additional AF-3. SUMOylation at Lys388 typically represses PR transcriptional activity and promotes nuclear retention (52). SUMO-1 modification of PR, mediated by the E3 ligase PIAS3, inhibits transcriptional activation on specific target genes. PR SUMOylation also contributes to autoinhibition and trans-repression, influencing receptor turnover and nuclear retention. In breast cancer cells, activated protein kinases can “lift” SUMOylation-dependent de-repression by favoring deSUMOylated phospho-PR, highlighting SUMOylation's role in modulating hormone-responsive gene expression as a function of context; crosstalk with growth factor–initiated signaling pathways results in PR phosphorylation and deSUMOylation.
PR is acetylated at Lys183 by p300, enhancing DNA-binding kinetics and transcriptional activity (53, 54). This modification influences PR's ability to recruit chromatin-modifying enzymes and interact with histone deacetylases (HDACs), contributing to dynamic gene regulation.
Mechanisms of Transcriptional Regulation
Despite sharing identical DNA-binding domains, PR-A and PR-B display remarkably distinct genomic binding profiles and transcriptional outputs. Early microarray studies in breast cancer cell lines engineered to express only PR-A or PR-B revealed that PR-B regulated significantly more progesterone-responsive genes, while PR-A targets a smaller distinct subset (55, 56). ChIP-seq analyses (22) later showed that PR-B binds approximately twice as many genomic sites as PR-A, with only partial overlap between their cistromes. Both isoforms recognize similar DNA motifs, suggesting that recruitment of accessory factors rather than direct DNA recognition determines binding specificity. These chromatin-level differences contribute significantly to the isoform-specific transcriptional programs observed in breast cancer models.
Role of Kinases in PR-Mediated Transcription
CDK regulation of PR activity
CDKs play a pivotal role in modulating PR isoform function. PR-B is extensively phosphorylated by CDK2 at 8 known sites, including Ser400, a modification that enhances its transcriptional activity and promotes rapid turnover. PR-A is comparatively resistant to CDK-mediated phosphorylation, due to differences in conformation and coregulator interactions, resulting in distinct regulatory properties (43, 57).
DYRK-mediated phosphorylation
Recent work from our group suggests that dual-specificity tyrosine-regulated kinases (DYRKs) further contribute to PR isoform-specific regulation (58). DYRK1A and DYRK1B exhibit isoform-specific regulatory effects on PR signaling in human fallopian tube epithelial (hFTE) cells. DYRK1A depletion uniquely impaired pro-tumorigenic phenotypes in PR-A+ cells and broadly reduced basal gene expression in the unliganded state, implicating it in cell cycle–related transcriptional control. In contrast, DYRK1B depletion disrupted ligand-dependent repression by PR-B, suggesting a distinct role in progestin-mediated signaling. These findings, along with emerging roles for DYRK kinases in DNA repair, point to a complex interface between PR isoform activity, kinase signaling, and faltering genomic stability in the early stages of tumor initiation.
Integrative signaling pathways
Beyond CDKs and DYRKs, PR isoforms integrate steroid hormone action with multiple signaling cascades, including MAPK and PI3K/Akt pathways (reviewed in (59)). PR-B, due to its additional phosphorylation sites, acts as a more responsive sensor to extracellular signals, modulating its transcriptional activity according to the cellular microenvironment. Unliganded PR-B is more localized at the cell membrane relative to PR-A (60). This isoform-specific localization may in part explain the heightened sensitivity to kinase signaling that allows PR-B to drive context-dependent gene expression programs that support cell proliferation and survival.
Coregulators and Partner Proteins
ERα crosstalk
PR isoforms interact differently with estrogen receptor alpha (ERα) signaling networks (21, 22). PR-B acts largely as a cooperative partner, co-binding with ERα at enhancer elements and amplifying estrogen-dependent transcriptional programs. In contrast, PR-A competes with ERα for DNA binding and coactivator resources, thereby antagonizing ERα activity. This antagonism is SUMO-dependent and includes sequestration of key coactivators, such as SRC-1 and p300, ultimately dampening ERα-driven gene expression. These differential interactions contribute to the distinct roles of PR-A and PR-B in modulating estrogen responses in breast cancer.
SWI/SNF complex interactions
Recruitment of the SWI/SNF chromatin remodeling complex also varies between isoforms (61). PR-B preferentially associates with BRG1-containing SWI/SNF complexes, facilitating chromatin remodeling at sites of transcriptional activation. PR-A, by contrast, exhibits reduced recruitment of these complexes, reinforcing its transcriptionally repressive character.
FOXO1 regulatory interactions
FOXO1, a critical regulator of cell cycle arrest and apoptosis, is differentially modulated by PR isoforms (62). PR-B phosphorylates and inactivates FOXO1 following progesterone stimulation, promoting cell cycle progression and proliferation. In opposition, PR-A stabilizes nuclear FOXO1, blocking progression through the cell cycle and contributing to repression of proliferation-associated genes.
DREAM complex modulation
The DREAM complex, a key regulator of cell cycle gene repression, is also differentially influenced by PR isoforms (58). PR-B disrupts DREAM complex formation through CDK-dependent phosphorylation events, enabling cell cycle entry and proliferation. PR-A, on the other hand, supports DREAM complex integrity, favoring maintenance of cell cycle arrest and contributing to its anti-proliferative effects while enabling G0-dependent phenotypes such as stem cell expansion (discussed in more detail in a later section).
Differential coregulator recruitment
PR-A and PR-B adopt distinct conformations that allow selective recruitment of coregulatory proteins (63). Mass spectrometry profiling has identified unique interactomes for each isoform (64). PR-A preferentially binds corepressors such as STAT1, GRB2, and NRIP1, while PR-B engages coactivators including KLF5, MLL2, and C3orf37. Both isoforms share interactions with TRIM33, KDM4B, and p300. Furthermore, PR-A demonstrates higher affinity for SMRT in the presence of antagonists and reduced association with coactivators like SRC-1 and SRC-2 upon agonist binding, in stark contrast to PR-B. These differential protein interactions underpin the isoform-specific transcriptional outcomes observed in various biological contexts.
Functional Consequences of Differential Regulation
A recent study from our group (unpublished) illustrates the above points by providing a detailed isoform-specific analysis of PR transcriptional activity in estrogen receptor-positive (ER+) breast cancer cells, with a unique focus on how cellular context influences PR function. While prior work has examined PR-A and PR-B individually, this is the first study to systematically compare their divergent transcriptional and phenotypic outputs across both 2D and 3D culture conditions (Fig. 4). Our findings reveal that PR-A and PR-B drive distinct gene expression programs and biological behaviors depending on the growth environment: PR-A promotes stem-like traits and tumor cell dissemination, whereas PR-B enhances proliferative and metabolic programs. These divergent activities were further validated using CUT&RUN chromatin profiling and in vivo MIND xenograft models, underscoring the relevance of isoform-specific and context-dependent PR signaling in tumor progression.
The cumulative effects of differential DNA binding, chromatin remodeling, coregulator recruitment, and post-translational modifications contribute to the unique transcriptional outputs of each isoform. PR-A is frequently associated with pro-inflammatory and stem-like gene signatures and has been linked to endocrine resistance and poor prognosis. In contrast, PR-B tends to activate pathways associated with proliferation and differentiation, correlating with more favorable outcomes. In the normal mammary gland, PR-A and PR-B are expressed at similar levels, but this balance is often disrupted in breast cancer, where an increased PR-A to PR-B ratio is a hallmark of aggressive disease. Together, these insights highlight the need for PR isoform-specific strategies in breast cancer diagnostics and treatment.
Physiological Roles of PR-A and PR-B
PRs play a vital role in developmental and reproductive biology. The role of progesterone signaling in normal mammary differentiation and proliferation required for pregnancy was described alongside other hormones in 1980 by Topper and Freeman (65). Since then, work by various groups defined the importance of each isoform in physiology for both normal and malignant tissues. It is now well-established that PR isoforms vary in level of expression depending on the tissue type, developmental and hormonal context.
As mentioned above, PR-A and PR-B are both expressed in healthy mammary tissue and altered expression ratios are associated with improper development and disease (66). Spatial and temporal changes in expression of PR-A and PR-B were shown through immunohistochemistry of mammary epithelial cells in mice during normal mammary gland development and pregnancy (67). PR-A is the only isoform present during development, but during pregnancy PR-A levels decrease and PR-B is highly expressed, specifically during alveologenesis. Colocalization of both isoforms only occurred in a small percentage of cells. In transgenic mice that overexpress one isoform or the other to skew the native ratio of the receptors, increased PR-B caused abnormal mammary gland development, specifically abnormal lobuloalveolar growth (68). Overexpression of PR-A induced ductal hyperplasia, a decrease in adhesion between cells, and increased ductal branching not seen in PR-B overexpressing mice (68, 69).
Ratios of the PR isoforms also fluctuate in other healthy tissues. For example, throughout the menstrual cycle both isoforms are expressed in the same cells at almost equivalent levels in breast tissues (70), but the ratio of A:B varies greatly in the uterus throughout the menstrual cycle (70, 71). PR-B overexpression has been found in ovarian, cervical, and endometrial cancers (72, 73), whereas PR-A seems to be dominantly expressed in noncancerous endometriosis (74). These findings not only suggest a specialized role of each isoform but implicate a fine-tuned system that is heterogeneous and context-dependent, but also readily changes in normal and abnormal tissue contexts.
Progesterone Receptor Isoforms in Breast Cancer
PRs have long been implicated in breast cancer biology. Exposure to progesterone (P4) is a life-long risk factor for breast cancer (75-81), and numerous PGR polymorphisms are linked to altered breast, endometrial, and ovarian cancer risk (82-87). While endogenous progesterone plays a physiological role throughout reproductive life, many studies linking “progesterone” exposure to breast cancer risk have instead evaluated synthetic progestins—analogs commonly used in hormone replacement therapy (HRT) and hormonal contraceptives. Evidence indicates that breast cancer risk varies according to the progestogen type, with synthetic progestins, especially in estrogen-progestin combinations, conferring a greater risk than natural progesterone. In malignant tissues, the ratio of PR isoform expression varies in half of the breast tumors assessed via immunoblotting (7), in which the protein levels of one isoform exceeded the other, but PR-A predominated in a majority of cases. Additionally, tumors with higher levels of PR-A seem to be delayed in differentiation relative to PR-B rich tumors (88). Since both PR isoforms are subject to post-translational modifications by signaling pathways commonly elevated in breast cancer, both their transcriptional and noncanonical activity is altered during cancer progression (reviewed in (59)). Our work suggests that phosphorylated PRs (p-PRs), specifically p-Ser294 PR, are associated with endocrine resistance and poor clinical outcomes. Approximately 54% of human ER+ breast cancers express abundant p-PRs (18), underscoring the relevance of PR PTMs and resulting signaling in disease progression.
Role in Endocrine Resistance and Cancer Stem Cell Regulation
Beyond their role in proliferation, PRs—particularly when phosphorylated—have been linked to the regulation of breast cancer stem cells (CSCs) (18). CSCs are long-lived, weakly proliferative cells that are enriched in aggressive breast cancers and are thought to contribute to therapy resistance, recurrence, and metastasis (89). Anti-estrogen therapies primarily target proliferating tumor cells but are less effective against CSCs. Importantly, proliferation and CSC self-renewal are distinct biological processes often governed by opposing signaling pathways (21-23), such that targeting one may inadvertently promote the other (24). The p-PR target gene ERBB2/HER2 (18) is known to regulate CSC self-renewal in ER+ breast cancers (25), suggesting that PR-driven pathways may underlie therapy resistance in part by maintaining the CSC population. This concept is further supported by findings that PR and PR-induced paracrine factors such as Wnt4 and RANKL are required for early dissemination of metastatic circulating tumor cells, including PR+ CSCs, in multiple models of HER2-driven mouse models (21).
Clinical Implications for PR-Targeted Therapies
There is growing clinical interest in developing and repurposing PR-targeted drugs for breast cancer treatment. Anti-progestins such as mifepristone and onapristone have demonstrated promising activity in preclinical models and early-phase clinical trials, including in patients with ER+/PR+ metastatic breast cancer (90). These compounds act by antagonizing PR-mediated transcriptional programs involved in stem cell renewal, epithelial–mesenchymal transition, and therapeutic resistance. A deeper understanding of isoform-specific (PR-A vs PR-B) and phosphorylation-dependent (eg, p-Ser294 PR) functions of PR may inform more precise deployment of PR-targeted strategies, particularly in endocrine-resistant disease.
Targeting PR signaling has moved from conceptual promise to clinical evaluation, most notably through the development and assessment of PR antagonists. In the MIPRA presurgical window trial (91), patients with luminal breast cancer and high PR-A/PR-B ratios (>1.5) received mifepristone for 2 weeks before surgery. The study observed a median 50% reduction in tumor Ki-67 expression, with 70% of patients achieving the prespecified proliferative response. Treatment increased tumor-infiltrating lymphocytes and upregulated markers of anti-proliferation (eg, p21) and apoptosis (eg, cleaved caspase-3), supporting the rationale for anti-progestin therapy, especially in PR-A–dominant disease.
Onapristone, a highly selective PR antagonist with minimal off-target activity at androgen and glucocorticoid receptors (unlike mifepristone), has also been evaluated clinically. In the phase 2 SMILE study, onapristone extended release (ONA-XR) plus fulvestrant was studied in ER+, HER2− metastatic breast cancer after progression on CDK4/6 inhibitors. Although no RECIST responses were observed among 11 evaluable patients, stable disease ≥5.5 months was achieved in 4 cases, and the combination was well-tolerated (92). In a phase 0, window-of-opportunity study (ONAWA), ONA-XR monotherapy in early-stage ER+/PR+ breast cancer reduced Ki-67 in tumors with high baseline PR expression and promoted features of endocrine sensitivity (93). Additional ongoing studies, such as anti-progestin combinations with letrozole, palbociclib (NCT05618613), or oral SERDs (NCT05618613), aim to test efficacy in endocrine-resistant settings.
Telapristone acetate (CDB-4124) and lonaprisan (ZK-230211), other selective progesterone receptor modulators (SPRMs)/SPRM-like agents with selectivity for PR, have been explored. Telapristone reached phase 2 studies in the neoadjuvant setting, but its development has stagnated (94). Lonaprisan was discontinued after phase 2 due to strategic decisions and unclear benefit (95).
The impact of PR-targeted therapy is highly context-dependent, both in terms of endogenous vs synthetic ligands and crosstalk with other steroid receptors (eg, AR, GR). Differences in ligand structure confer differential activity, with some synthetic progestins displaying agonist/antagonist effects or off-target actions, complicating the interpretation of past and ongoing studies. Recognizing and characterizing these nuances will be essential for optimizing clinical trial design and therapeutic selection as the field moves forward.
Together, these data highlight both the complexity and potential for the use of PR-targeted therapy in breast cancer. The clinical activity of PR antagonists appears to depend on factors including PR isoform expression (PR-A vs PR-B), presence of specific phosphorylation events (eg, p-Ser294), hormonal milieu, and the distinct pharmacologic properties of individual ligands (eg, partial agonists vs pure antagonists, steroid receptor selectivity). These considerations reinforce the need to stratify patients based on tumor PR biology and ligand-specific activity in future studies.
Conclusion
Progesterone receptor isoforms PR-A and PR-B exert distinct and dynamic roles in normal physiology and in breast cancer. Decades of research have uncovered their unique structural features, differential gene regulation, and complex interactions with oncogenic signaling pathways commonly dysregulated in cancer. Importantly, PR isoform balance and post-translational modifications profoundly influence tumor behavior, endocrine resistance, and cancer stem cell regulation, highlighting their clinical significance beyond traditional hormone responsiveness. As emerging studies continue to unravel the molecular mechanisms governing PR isoform-specific actions, opportunities arise to develop more targeted therapeutic strategies that disrupt PR-driven tumor progression. A deeper understanding of PR biology, particularly in the context of ER crosstalk and aberrant signaling networks, will be critical to improving outcomes for patients with breast cancer.
Abbreviations
- AF
activation function
- BUS
B-upstream segment
- CDK
cyclin dependent kinase
- CK2
casein kinase II
- CSC
cancer stem cell
- DBD
DNA-binding domain
- DYRK
dual-specificity tyrosine-regulated kinase
- ERα
estrogen receptor alpha
- LBD
ligand binding domain
- MAPK
mitogen-activated protein kinase
- NTD
N-terminal domain
- PR
progesterone receptor
- PR-A
progesterone receptor A
- PR-B
progesterone receptor B
- PTM
post-translational modification
Contributor Information
Noelle E Gillis, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Susan I Schmidt, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Microbiology, Immunology, and Cancer Biology Program, University of Minnesota, Minneapolis, MN 55455, USA.
Carol A Lange, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Department of Medicine, Division of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
Funding
This work was supported by the Department of Defense (BC181035, to C.A.L.), National Cancer Institute (NCI) R01 CA229697 (to C.A.L.) and K00CA245796 (to N.E.G.), and the Tickle Family Land Grant Endowed Chair in Breast Cancer Research (to C.A.L.).
Disclosures
Carol A. Lange is currently (7/2025-6/2026) President of the Endocrine Society but played no role in the review of this manuscript.
Data Availability
All raw and processed next-generation sequencing data associated with this manuscript is available for download from the NCBI Gene Expression Omnibus repository under accession code GSE293885. Bash and R scripts for analysis of RNA-seq data is available in a dedicated github repository https://github.com/negillis/PR-Isoforms-Analysis.
References
- 1. O'Malley BW, Sherman MR, Toft DO. Progesterone “receptors” in the cytoplasm and nucleus of chick oviduct target tissue. Proc Natl Acad Sci U S A. 1970;67(2):501‐508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Schrader WT, O'Malley BW. Progesterone-binding components of chick oviduct. IV. Characterization of purified subunits. J Biol Chem. 1972;247(1):51‐59. [PubMed] [Google Scholar]
- 3. Conneely OM, Kettelberger DM, Tsai MJ, Schrader WT, O'Malley BW. The chicken progesterone receptor A and B isoforms are products of an alternate translation initiation event. J Biol Chem. 1989;264(24):14062‐14064. [PubMed] [Google Scholar]
- 4. Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990;9(5):1603‐1614. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Dobson AD, Conneely OM, Beattie W, et al. Mutational analysis of the chicken progesterone receptor. J Biol Chem. 1989;264(7):4207‐4211. [PubMed] [Google Scholar]
- 6. Shyamala G, Schneider W, Schott D. Developmental regulation of murine mammary progesterone receptor gene expression. Endocrinology. 1990;126(6):2882‐2889. [DOI] [PubMed] [Google Scholar]
- 7. Graham JD, Yeates C, Balleine RL, et al. Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res. 1995;55(21):5063‐5068. [PubMed] [Google Scholar]
- 8. Hopp TA, Weiss HL, Hilsenbeck SG, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004;10(8):2751‐2760. [DOI] [PubMed] [Google Scholar]
- 9. Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BW. Reproductive functions of progesterone receptors. Recent Prog Horm Res. 2002;57(1):339‐355. [DOI] [PubMed] [Google Scholar]
- 10. Hill KK, Roemer SC, Churchill ME, Edwards DP. Structural and functional analysis of domains of the progesterone receptor. Mol Cell Endocrinol. 2012;348(2):418‐429. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Horwitz KB, Sheridan PL, Wei LL, Krett NL. Human progesterone receptors: synthesis, structure, and phosphorylation. Prog Clin Biol Res. 1990;322:41‐52. [PubMed] [Google Scholar]
- 12. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol. 1994;8(10):1347‐1360. [DOI] [PubMed] [Google Scholar]
- 13. Wei LL, Gonzalez-Aller C, Wood WM, Miller LA, Horwitz KB. 5′-Heterogeneity in human progesterone receptor transcripts predicts a new amino-terminal truncated “C”-receptor and unique A-receptor messages. Mol Endocrinol. 1990;4(12):1833‐1840. [DOI] [PubMed] [Google Scholar]
- 14. Price TM, Dai Q. The role of a mitochondrial progesterone receptor (PR-M) in progesterone action. Semin Reprod Med. 2015;33(3):185‐194. [DOI] [PubMed] [Google Scholar]
- 15. Hirata S, Shoda T, Kato J, Hoshi K. Novel isoforms of the mRNA for human female sex steroid hormone receptors. J Steroid Biochem Mol Biol. 2002;83(1-5):25‐30. [DOI] [PubMed] [Google Scholar]
- 16. Samalecos A, Gellersen B. Systematic expression analysis and antibody screening do not support the existence of naturally occurring progesterone receptor (PR)-C, PR-M, or other truncated PR isoforms. Endocrinology. 2008;149(11):5872‐5887. [DOI] [PubMed] [Google Scholar]
- 17. Meyer ME, Pornon A, Ji JW, Bocquel MT, Chambon P, Gronemeyer H. Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J. 1990;9(12):3923‐3932. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Zhang Y, Beck CA, Poletti A, et al. Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol. 1997;11(6):823‐832. [DOI] [PubMed] [Google Scholar]
- 19. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389(6652):753‐758. [DOI] [PubMed] [Google Scholar]
- 20. Tetel MJ, Jung S, Carbajo P, Ladtkow T, Skafar DF, Edwards DP. Hinge and amino-terminal sequences contribute to solution dimerization of human progesterone receptor. Mol Endocrinol. 1997;11(8):1114‐1128. [DOI] [PubMed] [Google Scholar]
- 21. Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ERalpha action in breast cancer. Nature. 2015;523(7560):313‐317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Singhal H, Greene ME, Zarnke AL, et al. Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling. Oncotarget. 2018;9(4):4282‐4300. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Khorasanizadeh S, Rastinejad F. Nuclear-receptor interactions on DNA-response elements. Trends Biochem Sci. 2001;26(6):384‐390. [DOI] [PubMed] [Google Scholar]
- 24. Zilliacus J, Wright AP, Carlstedt-Duke J, Gustafsson JA. Structural determinants of DNA-binding specificity by steroid receptors. Mol Endocrinol. 1995;9(4):389‐400. [DOI] [PubMed] [Google Scholar]
- 25. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237(4812):268‐275. [DOI] [PubMed] [Google Scholar]
- 26. Cato AC, Miksicek R, Schütz G, Arnemann J, Beato M. The hormone regulatory element of mouse mammary tumour virus mediates progesterone induction. EMBO J. 1986;5(9):2237‐2240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Cato AC, Henderson D, Ponta H. The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. EMBO J. 1987;6(2):363‐368. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Darbre P, Page M, King RJ. Androgen regulation by the long terminal repeat of mouse mammary tumor virus. Mol Cell Biol. 1986;6(8):2847‐2854. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Nelson CC, Hendy SC, Shukin RJ, et al. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. Mol Endocrinol. 1999;13(12):2090‐2107. [DOI] [PubMed] [Google Scholar]
- 30. Luisi BF, Xu WX, Otwinowski Z, Freedman LP, Yamamoto KR, Sigler PB. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature. 1991;352(6335):497‐505. [DOI] [PubMed] [Google Scholar]
- 31. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci U S A. 2004;101(14):4758‐4763. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Lieberman BA, Bona BJ, Edwards DP, Nordeen SK. The constitution of a progesterone response element. Mol Endocrinol. 1993;7(4):515‐527. [DOI] [PubMed] [Google Scholar]
- 33. Nordeen SK, Suh BJ, Kühnel B, Hutchison CA 3rd. Structural determinants of a glucocorticoid receptor recognition element. Mol Endocrinol. 1990;4(12):1866‐1873. [DOI] [PubMed] [Google Scholar]
- 34. Roche PJ, Hoare SA, Parker MG. A consensus DNA-binding site for the androgen receptor. Mol Endocrinol. 1992;6(12):2229‐2235. [DOI] [PubMed] [Google Scholar]
- 35. DeMarzo AM, Beck CA, Onate SA, Edwards DP. Dimerization of mammalian progesterone receptors occurs in the absence of DNA and is related to the release of the 90-kDa heat shock protein. Proc Natl Acad Sci U S A. 1991;88(1):72‐76. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol. 1993;7(10):1256‐1265. [DOI] [PubMed] [Google Scholar]
- 37. Carbajo P, Christensen K, Edwards DP, Skafar DF. Binding of [3H]progesterone to the human progesterone receptor: differences between individual and mixed isoforms. Endocrinology. 1996;137(6):2339‐2346. [DOI] [PubMed] [Google Scholar]
- 38. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol. 1993;7(10):1244‐1255. [DOI] [PubMed] [Google Scholar]
- 39. Condon JC, Hardy DB, Kovaric K, Mendelson CR. Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-kappaB may contribute to the onset of labor through inhibition of PR function. Mol Endocrinol. 2006;20(4):764‐775. [DOI] [PubMed] [Google Scholar]
- 40. Wei LL, Norris BM, Baker CJ. An N-terminally truncated third progesterone receptor protein, PR(C), forms heterodimers with PR(B) but interferes in PR(B)-DNA binding. J Steroid Biochem Mol Biol. 1997;62(4):287‐297. [DOI] [PubMed] [Google Scholar]
- 41. Boonyaratanakornkit V, Scott MP, Ribon V, et al. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell. 2001;8(2):269‐280. [DOI] [PubMed] [Google Scholar]
- 42. Migliaccio A, Piccolo D, Castoria G, et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998;17(7):2008‐2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Narayanan R, Adigun AA, Edwards DP, Weigel NL. Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol. 2005;25(1):264‐277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Skildum A, Faivre E, Lange CA. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol. 2005;19(2):327‐339. [DOI] [PubMed] [Google Scholar]
- 45. Lange CA. Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol Endocrinol. 2004;18(2):269‐278. [DOI] [PubMed] [Google Scholar]
- 46. Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL. Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol. 1995;9(8):1029‐1040. [DOI] [PubMed] [Google Scholar]
- 47. Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL. Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J Biol Chem. 1994;269(49):31034‐31040. [PubMed] [Google Scholar]
- 48. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A. 2000;97(3):1032‐1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA. Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol. 2003;17(4):628‐642. [DOI] [PubMed] [Google Scholar]
- 50. Hagan CR, Regan TM, Dressing GE, Lange CA. ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells. Mol Cell Biol. 2011;31(12):2439‐2452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Takimoto GS, Tung L, Abdel-Hafiz H, et al. Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. J Steroid Biochem Mol Biol. 2003;85(2-5):209‐219. [DOI] [PubMed] [Google Scholar]
- 52. Abdel-Hafiz H, Dudevoir ML, Horwitz KB. Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation. J Biol Chem. 2009;284(14):9099‐9108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Chung HH, Sze SK, Tay AS, Lin VC. Acetylation at lysine 183 of progesterone receptor by p300 accelerates DNA binding kinetics and transactivation of direct target genes. J Biol Chem. 2014;289(4):2180‐2194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Gujral P, Mahajan V, Lissaman AC, Ponnampalam AP. Histone acetylation and the role of histone deacetylases in normal cyclic endometrium. Reprod Biol Endocrinol. 2020;18(1):84. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem. 2002;277(7):5209‐5218. [DOI] [PubMed] [Google Scholar]
- 56. Khan JA, Bellance C, Guiochon-Mantel A, Lombes M, Loosfelt H. Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line. PLoS One. 2012;7(9):e45993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Pierson-Mullany LK, Lange CA. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol. 2004;24(24):10542‐10557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Mauro LJ, Seibel MI, Diep CH, et al. Progesterone receptors promote quiescence and Ovarian cancer cell phenotypes via DREAM in p53-mutant fallopian tube models. J Clin Endocrinol Metab. 2021;106(7):1929‐1955. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Dwyer AR, Truong TH, Ostrander JH, Lange CA. 90 YEARS OF PROGESTERONE: steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide. J Mol Endocrinol. 2020;65(1):T35‐T48. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP. The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007;21(2):359‐375. [DOI] [PubMed] [Google Scholar]
- 61. Rayasam GV, Elbi C, Walker DA, et al. Ligand-specific dynamics of the progesterone receptor in living cells and during chromatin remodeling in vitro. Mol Cell Biol. 2005;25(6):2406‐2418. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Diep CH, Knutson TP, Lange CA. Active FOXO1 is a key determinant of isoform-specific progesterone receptor transactivation and senescence programming. Mol Cancer Res. 2016;14(2):141‐162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Mann MD, Wang M, Ferreon JC, et al. Structural proteomics defines a sequential priming mechanism for the progesterone receptor. Nat Commun. 2025;16(1):4403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Pateetin P, Hutvagner G, Bajan S, Padula MP, McGowan EM, Boonyaratanakornkit V. Triple SILAC identified progestin-independent and dependent PRA and PRB interacting partners in breast cancer. Sci Data. 2021;8(1):100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Topper YJ, Freeman CS. Multiple hormone interactions in the developmental biology of the mammary gland. Physiol Rev. 1980;60(4):1049‐1106. [DOI] [PubMed] [Google Scholar]
- 66. Jacobsen BM, Richer JK, Schittone SA, Horwitz KB. New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. J Biol Chem. 2002;277(31):27793‐27800. [DOI] [PubMed] [Google Scholar]
- 67. Aupperlee MD, Smith KT, Kariagina A, Haslam SZ. Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology. 2005;146(8):3577‐3588. [DOI] [PubMed] [Google Scholar]
- 68. Shyamala G, Yang X, Cardiff RD, Dale E. Impact of progesterone receptor on cell-fate decisions during mammary gland development. Proc Natl Acad Sci U S A. 2000;97(7):3044‐3049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH, Dale E. Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci U S A. 1998;95(2):696‐701. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70. Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002;72(2):163‐172. [DOI] [PubMed] [Google Scholar]
- 71. Mangal RK, Wiehle RD, Poindexter AN 3rd, Weigel NL. Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J Steroid Biochem Mol Biol. 1997;63(4-6):195‐202. [DOI] [PubMed] [Google Scholar]
- 72. Farr CJ, Easty DJ, Ragoussis J, Collignon J, Lovell-Badge R, Goodfellow PN. Characterization and mapping of the human SOX4 gene. Mamm Genome. 1993;4(10):577‐584. [DOI] [PubMed] [Google Scholar]
- 73. Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Clinical implication of expression of progesterone receptor form A and B mRNAs in secondary spreading of gynecologic cancers. J Steroid Biochem Mol Biol. 1997;62(5-6):449‐454. [DOI] [PubMed] [Google Scholar]
- 74. Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000;85(8):2897‐2902. [DOI] [PubMed] [Google Scholar]
- 75. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 2002;4(5):197‐201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362(9392):1330‐1331. [DOI] [PubMed] [Google Scholar]
- 77. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006;24(33):e49‐e50. [DOI] [PubMed] [Google Scholar]
- 78. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999;84(12):4559‐4565. [DOI] [PubMed] [Google Scholar]
- 79. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer. 2006;118(5):1285‐1291. [DOI] [PubMed] [Google Scholar]
- 80. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst. 2000;92(4):328‐332. [DOI] [PubMed] [Google Scholar]
- 81. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321‐333. [DOI] [PubMed] [Google Scholar]
- 82. De Vivo I, Huggins GS, Hankinson SE, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A. 2002;99(19):12263‐12268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83. Johnatty SE, Spurdle AB, Beesley J, et al. Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies. Breast Cancer Res Treat. 2008;109(1):91‐99. [DOI] [PubMed] [Google Scholar]
- 84. Kotsopoulos J, Tworoger SS, De Vivo I, et al. +331g/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer. Int J Cancer. 2009;125(7):1685‐1691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85. Romano A, Lindsey PJ, Fischer DC, et al. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. Gynecol Oncol. 2006;101(2):287‐295. [DOI] [PubMed] [Google Scholar]
- 86. Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW. Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol. 2005;161(5):442‐451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Huggins GS, Wong JY, Hankinson SE, De Vivo I. GATA5 activation of the progesterone receptor gene promoter in breast cancer cells is influenced by the +331G/A polymorphism. Cancer Res. 2006;66(3):1384‐1390. [DOI] [PubMed] [Google Scholar]
- 88. Bamberger AM, Milde-Langosch K, Schulte HM, Löning T. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res. 2000;54(1):32‐37. [DOI] [PubMed] [Google Scholar]
- 89. Lawson DA, Bhakta NR, Kessenbrock K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015;526(7571):131‐135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90. Liberty A, Edelman A, Bernhardt SM. The emerging role of progesterone receptor modulators in breast physiology, cancer prevention and treatment. BMJ Sex Reprod Health. Published online April 04, 2025. doi: 10.1136/bmjsrh-2024-202662. [DOI] [PubMed] [Google Scholar]
- 91. Elia A, Saldain L, Vanzulli SI, et al. Beneficial effects of mifepristone treatment in patients with breast cancer selected by the progesterone receptor isoform ratio: results from the MIPRA trial. Clin Cancer Res. 2023;29(5):866‐877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Kamaraju S, Fowler AM, Tarima S, et al. A phase II trial of onapristone and fulvestrant for patients with ER+ and HER2- metastatic breast cancer. Clin Breast Cancer. 2025;25(3):251‐260. [DOI] [PubMed] [Google Scholar]
- 93. Bellet M, Morales S, Gasol A, et al. Abstract P1-07-02: primary results of ONAWA (SOLTI-1802) trial: a window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). Cancer Res. 2022;82(4_Supplement):P1-07-02‐P1-07-02. [Google Scholar]
- 94. Lee O, Pilewskie M, Karlan S, et al. Local transdermal delivery of telapristone acetate through breast skin, compared with oral treatment: a randomized double-blind, placebo-controlled phase II trial. Clin Pharmacol Ther. 2021;109(3):728‐738. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95. Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson JFR. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013;24(10):2543‐2548. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All raw and processed next-generation sequencing data associated with this manuscript is available for download from the NCBI Gene Expression Omnibus repository under accession code GSE293885. Bash and R scripts for analysis of RNA-seq data is available in a dedicated github repository https://github.com/negillis/PR-Isoforms-Analysis.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.